Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized amikacin (BAY 41-6551) as adjunctive therapy in mechanically ventilated patients with gram-negative pneumonia
2013-001048-73Phase 3Completed
- Sponsor
- Bayer
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumonia comparing Aerosolized amikacin plus intravenous antibiotics with Aerosolized saline placebo plus intravenous antibiotics (2 arms). Primary endpoint: Clinical Success in mITT population. Started May 2013; status: completed.
02
Drugs
amikacin
03
Conditions
pneumonia
Beyond the preview
Go deeper on 2013-001048-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001048-73.